July 19 | 2021
2cureX receives important ISO 13485:2016 certification
Read more
July 1 | 2021
2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer
Read more
June 7 | 2021
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Read more
June 4 | 2021
REDEYE releases an updated 2cureX Equity Research Report
Read more
May 20 | 2021
2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting
Read more
May 6 | 2021
Mangold Fondkommission AB published an Analyst Report on 2cureX
Read more
April 27 | 2021
2cureX’s CEO Fernando Andreu is buying shares in the company
Read more
April 26 | 2021
2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK
Read more
April 26 | 2021
Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
Read more
March 2 | 2021
2cureX Clinical Newsletter
Read more
March 1 | 2021
2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.
Read more
February 4 | 2021
IndiTreat® selected to prestigious multinational ovarian cancer project.
Read more
January 21 | 2021
Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
December 23 | 2020
Key achievements in 2020 – an IndiTreat ® Launch year
Read more
November 26 | 2020
2cureX launches new website
Read more
November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more
November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more